



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2024

Date: 18th May, 2024

The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

ISIN: INE915B01019, INE915B07024
BSE Scrip Code: 532305, 957989

NSE Symbol: INDSWFTLAB

SUBJECT: INTIMATION UNDER REGULATION 30 REGARDING INCORPORATION OF WHOLLY OWNED SUBSIDIARY

Dear Sir/Ma'am,

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (hereinafter "SEBI Listing Regulations") read with Para A-Part A of Schedule III of the SEBI Listing Regulations, including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force and with reference to our earlier intimation dated 19th April, 2024 we now inform the exchanges that the wholly owned subsidiary of the Company has been incorporated in Dubai, United Arab Emirates (UAE) in the name and style of "ISLL Middle East L.L.C-FZ". The certificate of incorporation has been received on 17th May, 2024 from the Registrar of Companies of the Meydan – Free Zone.

Further the details required under SEBI Master Circular issued vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed herewith as Annexure I.

The above is for your information and records.

With Regards,
For **IND-SWIFT LABORATORIES LTD.**



PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



Annexure I

S. No.	Particulars	Details
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Name: ISLL Middle East L.L.C-FZ Size/Turnover: Not applicable (newly incorporated)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The newly incorporated Company being a wholly owned subsidiary to be considered as Related Party. The initial investment in the said wholly owned subsidiary would be a Related Party Transaction and said investment made by the Company shall be on Arms’ Length basis. The Company is the Promoter of the said wholly owned subsidiary. Save and except as mentioned above, the Company is not interested in any other manner
3.	Industry to which the entity being acquired belongs	Pharmaceuticals (Newly incorporated, yet to commence business operations)
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The WOS intends to strategically invest in pharmaceutical and allied activities. This includes exploring potential acquisitions, tie-ups, or joint ventures. Additionally, the Company aims to establish and operate pharmaceutical manufacturing units.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	NA
6.	Indicative time period for completion of the acquisition;	NA
7.	Nature of consideration - whether cash consideration or share swap and details of the same;	Subscription to 100% of the equity in WOS, to be paid in cash.
8.	Cost of acquisition or the price at which the shares are acquired	NA
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	100%
10.	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Date of Incorporation: 17-May-2024 Regd. Office: Meydan Grandstand, 6 th floor, Meydan Road, Nad Al Sheba, Dubai, U.A.E History / Turnover: Not Applicable (Newly incorporated)